Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology

被引：252

作者：

Sepulveda, Antonia R. ^{[1
]}

Hamilton, Stanley R. ^{[2
]}

Allegra, Carmen J. ^{[3
]}

Grody, Wayne ^{[4
]}

Cushman-Vokoun, Allison M. ^{[5
]}

Funkhouser, William K. ^{[6
]}

Kopetz, Scott E. ^{[2
]}

Lieu, Christopher ^{[7
]}

Lindor, Noralane M. ^{[8
]}

Minsky, Bruce D. ^{[2
]}

Monzon, Federico A. ^{[9
]}

Sargent, Daniel J. ^{[10
]}

Singh, Veena M. ^{[11
]}

Willis, Joseph ^{[12
]}

Clark, Jennifer ^{[13
]}

Colasacco, Carol ^{[14
]}

Rumble, R. Bryan ^{[15
]}

Temple-Smolkin, Robyn ^{[16
]}

Ventura, Christina B. ^{[14
]}

Nowak, Jan A. ^{[17
]}

机构：

[1] Columbia Univ, New York, NY USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Florida, Med Ctr, Gainesville, FL USA

[4] UCLA, Los Angeles, CA USA

[5] Univ Nebraska, Med Ctr, Omaha, NE 68182 USA

[6] Univ N Carolina, Sch Med, Chapel Hill, NC USA

[7] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA

[8] Mayo Clin, Scottsdale, AZ USA

[9] Castle Biosci, Friendswood, TX USA

[10] Mayo Clin, Rochester, MN USA

[11] Biocept, San Diego, CA USA

[12] Case Western Reserve Univ, Cleveland, OH USA

[13] Amer Soc Clin Pathologists, Washington, DC USA

[14] Coll Amer Pathologists, Northfield, MN USA

[15] Amer Soc Clin Oncol, Alexandria, VA USA

[16] Assoc Mol Pathol, Bethesda, MD USA

[17] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 13期

关键词：

RECEPTOR MONOCLONAL-ANTIBODIES; KRAS MUTATION DETECTION; ANTI-EGFR THERAPY; III COLON-CANCER; K-RAS MUTATIONS; MICROSATELLITE-INSTABILITY; PIK3CA MUTATION; ADJUVANT CHEMOTHERAPY; 1ST-LINE TREATMENT; PTEN EXPRESSION;

D O I：

10.1200/JCO.2016.71.9807

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Molecular testing of colorectal cancers (CRCs) to improve patient care and outcomes of targeted and conventional therapies has been the center of many recent studies, including clinical trials. Evidence-based recommendations for the molecular testing of CRC tissues to guide epidermal growth factor receptor (EGFR) -targeted therapies and conventional chemotherapy regimens are warranted in clinical practice. The purpose of this guideline is to develop evidence-based recommendations to help establish standard molecular biomarker testing for CRC through a systematic review of the literature. Methods The American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to develop an evidence-based guideline to help establish standard molecular biomarker testing, guide targeted therapies, and advance personalized care for patients with CRC. A comprehensive literature search that included over 4,000 articles was conducted to gather data to inform this guideline. Results Twenty-one guideline statements (eight recommendations, 10 expert consensus opinions and three no recommendations) were established. Recommendations Evidence supports mutational testing for genes in the EGFR signaling pathway, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize molecular testing for predictive and prognostic molecular biomarkers involve selection of assays, type of specimens to be tested, timing of ordering of tests and turnaround time for testing results. Additional information is available at: www.asco.org/CRC-markers-guideline and www.asco.org/guidelineswiki (C) 2017 by American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, American Society of Clinical Oncology, and American Society for Investigative Pathology

引用

页码：1453 / +

页数：37

共 148 条

[1] A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer [J].